Incyte Acquires Escient Pharmaceuticals 2024

Incyte announced the acquisition of Escient Pharmaceuticals on April 23, 2024. The transaction adds EP262 and EP547 candidates to Incyte's pipeline, targeting atopic dermatitis, chronic inducible urticaria, and chronic urticaria. This acquisition strengthens Incyte's inflammation and autoimmunity portfolio.